JP5544296B2 - 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 - Google Patents

代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 Download PDF

Info

Publication number
JP5544296B2
JP5544296B2 JP2010534263A JP2010534263A JP5544296B2 JP 5544296 B2 JP5544296 B2 JP 5544296B2 JP 2010534263 A JP2010534263 A JP 2010534263A JP 2010534263 A JP2010534263 A JP 2010534263A JP 5544296 B2 JP5544296 B2 JP 5544296B2
Authority
JP
Japan
Prior art keywords
piperidin
alkyl
yloxy
phenyl
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010534263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503210A (ja
JP2011503210A5 (enExample
Inventor
フイ ホン，
シャン スー，
チアシン ユー，
ラジンダー シン，
イハブ エス． ダウィッシュ，
サンバイアー トータ，
Original Assignee
ライジェル ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライジェル ファーマシューティカルズ， インコーポレイテッド filed Critical ライジェル ファーマシューティカルズ， インコーポレイテッド
Publication of JP2011503210A publication Critical patent/JP2011503210A/ja
Publication of JP2011503210A5 publication Critical patent/JP2011503210A5/ja
Application granted granted Critical
Publication of JP5544296B2 publication Critical patent/JP5544296B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2010534263A 2007-11-16 2008-11-17 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 Expired - Fee Related JP5544296B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US98872107P 2007-11-16 2007-11-16
US60/988,721 2007-11-16
US99055807P 2007-11-27 2007-11-27
US99055407P 2007-11-27 2007-11-27
US60/990,558 2007-11-27
US60/990,554 2007-11-27
US99118907P 2007-11-29 2007-11-29
US60/991,189 2007-11-29
US1392407P 2007-12-14 2007-12-14
US61/013,924 2007-12-14
PCT/US2008/083801 WO2009065131A1 (en) 2007-11-16 2008-11-17 Carboxamide, sulfonamide and amine compounds for metabolic disorders

Publications (3)

Publication Number Publication Date
JP2011503210A JP2011503210A (ja) 2011-01-27
JP2011503210A5 JP2011503210A5 (enExample) 2012-12-20
JP5544296B2 true JP5544296B2 (ja) 2014-07-09

Family

ID=40352415

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010534263A Expired - Fee Related JP5544296B2 (ja) 2007-11-16 2008-11-17 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物

Country Status (15)

Country Link
US (3) US8119809B2 (enExample)
EP (1) EP2231600B1 (enExample)
JP (1) JP5544296B2 (enExample)
KR (1) KR101573091B1 (enExample)
CN (1) CN101910131B (enExample)
AU (3) AU2008322426C1 (enExample)
BR (1) BRPI0820171B8 (enExample)
CA (1) CA2705947C (enExample)
EA (1) EA019509B1 (enExample)
ES (1) ES2552733T3 (enExample)
IL (1) IL205624A (enExample)
MX (2) MX2010005298A (enExample)
NZ (1) NZ585298A (enExample)
WO (1) WO2009065131A1 (enExample)
ZA (1) ZA201003412B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2079694B1 (en) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
KR101573091B1 (ko) 2007-11-16 2015-11-30 리겔 파마슈티칼스, 인크. 대사성 장애를 위한 카르복스아미드, 술폰아미드 및 아민 화합물
CA2707047C (en) * 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
CA2722139C (en) * 2008-04-23 2017-04-11 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
HRP20150355T1 (hr) 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
NZ594556A (en) 2009-01-28 2013-11-29 Rigel Pharmaceuticals Inc Carboxamide compounds and methods for using the same
MX2011013016A (es) 2009-06-05 2012-04-20 Link Medicine Corp Derivados de aminopirrolidinona y usos de los mismos.
CN102666485A (zh) * 2009-09-21 2012-09-12 霍夫曼-拉罗奇有限公司 烯烃羟吲哚衍生物及其用于治疗肥胖症，糖尿病和高脂血症的应用
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011115106A1 (ja) * 2010-03-16 2011-09-22 国立大学法人 東京大学 擬似運動療法のための医薬
WO2011123681A1 (en) * 2010-03-31 2011-10-06 Rigel Pharmaceuticals, Inc. Methods for using carboxamide, sulfonamide and amine compounds
TW201211053A (en) * 2010-05-10 2012-03-16 Nissan Chemical Ind Ltd Spiro compound and drug for activating adiponectin receptor
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
CA2806341C (en) 2010-07-29 2020-03-24 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
JP5769326B2 (ja) 2010-10-19 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｈｏキナーゼ阻害薬
US9005909B2 (en) 2011-01-06 2015-04-14 Rigel Pharmaceuticals, Inc. Whole blood assay for measuring AMPK activation
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9409884B2 (en) * 2012-02-01 2016-08-09 Rigel Pharmaceuticals, Inc. 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6233855B2 (ja) * 2012-08-08 2017-11-22 ノバルティス・ティーアゲズントハイト・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｔｉｅｒｇｅｓｕｎｄｈｅｉｔ Ａｇ 殺虫剤としての置換されたアジン類
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
MX2020011652A (es) 2013-07-31 2022-09-27 Novartis Ag Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
WO2015046595A1 (ja) 2013-09-30 2015-04-02 国立大学法人東京大学 アディポネクチン受容体活性化化合物
EP3231802B1 (en) * 2014-12-08 2021-05-05 Jiangsu Hengrui Medicine Co., Ltd. Pyridine-2-carboxamide derivatives, preparation method therefor and pharmaceutical uses thereof
EP3959205B1 (en) * 2019-04-26 2025-11-12 Merck Sharp & Dohme LLC Process for the preparation of intermediates useful for making (2s,5r)-7-oxo-n-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
WO2022072397A1 (en) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820115D0 (en) * 1988-08-24 1988-09-28 Ici Plc Insecticidal compounds
US6137002A (en) * 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
NZ331490A (en) 1996-03-28 2000-06-23 Glaxo Group Ltd Pyrrolopyrrolone derivatives for the treatment or prophylaxis of inflammatory disease such as chronic bronchitis, obstructive pulmonary disease and asthma
GB9715584D0 (en) 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
DE19738615A1 (de) * 1997-09-04 1999-03-11 Clariant Gmbh Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
EP1107758A2 (en) 1998-08-28 2001-06-20 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
DK1218380T3 (da) * 1999-10-08 2004-03-15 Gruenenthal Gmbh Bicykliske imidazo-3-yl-aminoderivater substitueret i seksledsringen
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
WO2002089749A2 (en) 2001-05-10 2002-11-14 Abbott Gmbh & Co.Kg Arylsulfonamide ethers, and methods of use thereof
BR0212123A (pt) 2001-08-24 2004-07-20 Upjohn Co 7-aza[2.2.1]biciclo-heptanos substituìdos com arila para o tratamento de doenças
EP1425286B1 (en) 2001-09-12 2007-02-28 Pharmacia & Upjohn Company LLC Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
CA2476681A1 (en) 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
MXPA04007083A (es) * 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
AU2003245669A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
AU2003254157A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
EP1569646A2 (en) 2002-12-13 2005-09-07 Smithkline Beecham Corporation Piperidine derivatives as ccr5 antagonists
US7208491B2 (en) * 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
GB0314054D0 (en) 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
JP2007516256A (ja) 2003-12-12 2007-06-21 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20050234095A1 (en) * 2004-03-25 2005-10-20 Wenge Xie Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
CN1960727B (zh) * 2004-06-02 2011-02-16 霍夫曼-拉罗奇有限公司 用作组胺-3受体的配体的萘衍生物
CN1972926B (zh) * 2004-06-21 2011-02-16 霍夫曼-拉罗奇有限公司 作为组胺受体拮抗剂的吲哚衍生物
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
ATE517882T1 (de) 2004-10-19 2011-08-15 Hoffmann La Roche Chinolinderivate
AU2005300150A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
CN101098870B (zh) 2004-11-08 2010-11-03 万有制药株式会社 新型稠环咪唑衍生物
US20080125432A1 (en) 2004-12-01 2008-05-29 Devgen Nv 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
BRPI0517211B8 (pt) 2004-12-17 2021-05-25 Glenmark Pharmaceuticals Sa composto, composição farmacêutica e seu uso.
EP1838312A4 (en) 2004-12-17 2010-01-20 Smithkline Beecham Corp CHEMICAL COMPOUNDS
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
US20060187891A1 (en) 2005-02-24 2006-08-24 Jussi-Pekka Sairanen Provision of services in a communication system
CA2599987A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
US7893267B2 (en) 2005-03-14 2011-02-22 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
EP1863810A4 (en) 2005-03-22 2010-03-31 Astrazeneca Ab NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
JP2009500419A (ja) 2005-07-05 2009-01-08 アリックス セラピューティクス、インコーポレイテッド 立体異性体のピリジル及びピリドニル化合物並びに消化管障害及び中枢神経系障害の治療方法
CA2622677A1 (en) * 2005-09-23 2007-04-05 Richard Schumacher Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
KR101047204B1 (ko) * 2005-11-30 2011-07-06 에프. 호프만-라 로슈 아게 Ｈ3 조절제로서 사용하기 위한1,1-다이옥소-싸이오모폴린일 인돌일 메탄온 유도체
ES2342979T3 (es) * 2005-11-30 2010-07-20 F. Hoffmann-La Roche Ag Derivados de indol-2-carboxamida sustituidos en 5.
CN101316840B (zh) * 2005-11-30 2012-08-08 霍夫曼-拉罗奇有限公司 1,5-取代的吲哚-2-基酰胺衍生物
WO2007075688A2 (en) * 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine h3 antagonists
JP2009524689A (ja) 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物
TW200738711A (en) 2006-01-25 2007-10-16 Smithkline Beecham Corp Chemical compounds
WO2007098086A2 (en) * 2006-02-17 2007-08-30 Avalon Pharmaceuticals Hydroxypiperidine derivatives and uses thereof
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
NL2000581C2 (nl) 2006-04-20 2008-01-03 Pfizer Prod Inc Aangecondenseerde fenylamidoheterocyclische verbindingen.
WO2007125405A2 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
EP2032566A4 (en) 2006-06-12 2009-07-08 Merck Frosst Canada Ltd AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE
CA2654098A1 (en) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
TW200821303A (en) 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
EP2079694B1 (en) * 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
JP2010527915A (ja) * 2007-04-26 2010-08-19 アバロン ファーマシューティカルズ，インコーポレイテッド 多重環化合物及びその用途
SG183049A1 (en) * 2007-07-20 2012-08-30 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
KR101573091B1 (ko) 2007-11-16 2015-11-30 리겔 파마슈티칼스, 인크. 대사성 장애를 위한 카르복스아미드, 술폰아미드 및 아민 화합물
CA2707047C (en) * 2007-12-12 2017-11-28 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EA018703B1 (ru) * 2008-04-07 2013-10-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
CA2722139C (en) 2008-04-23 2017-04-11 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
JP2010090067A (ja) * 2008-10-09 2010-04-22 Taisho Pharmaceutical Co Ltd 含窒素複素環誘導体

Also Published As

Publication number Publication date
MX2010005298A (es) 2010-06-30
US8119809B2 (en) 2012-02-21
EP2231600A1 (en) 2010-09-29
ES2552733T3 (es) 2015-12-01
US20120115838A1 (en) 2012-05-10
AU2017202766A1 (en) 2017-05-18
US8569340B2 (en) 2013-10-29
BRPI0820171B1 (pt) 2021-02-23
CA2705947C (en) 2016-08-09
AU2008322426C1 (en) 2014-10-23
CN101910131A (zh) 2010-12-08
JP2011503210A (ja) 2011-01-27
KR101573091B1 (ko) 2015-11-30
KR20100097695A (ko) 2010-09-03
MX382569B (es) 2025-03-13
US20140051673A1 (en) 2014-02-20
AU2008322426A1 (en) 2009-05-22
AU2014202572A1 (en) 2014-06-05
BRPI0820171B8 (pt) 2021-05-25
AU2014202572B2 (en) 2017-02-02
HK1148525A1 (en) 2011-09-09
US20090170829A1 (en) 2009-07-02
EA201070619A1 (ru) 2010-12-30
CN101910131B (zh) 2014-04-23
AU2017202766B2 (en) 2019-03-21
AU2008322426B2 (en) 2014-06-05
NZ585298A (en) 2012-08-31
WO2009065131A1 (en) 2009-05-22
EP2231600B1 (en) 2015-07-29
ZA201003412B (en) 2011-02-23
EA019509B1 (ru) 2014-04-30
CA2705947A1 (en) 2009-05-22
US9174964B2 (en) 2015-11-03
IL205624A0 (en) 2010-11-30
IL205624A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
JP5544296B2 (ja) 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
JP5650540B2 (ja) 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
JP5964906B2 (ja) 代謝障害の処置のためのカルボキサミド化合物
EP2598483A1 (en) Ampk-activating heterocyclic compounds and methods for using the same
EP2079694A1 (en) N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
HK1148525B (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders
HK1148524B (en) Carboxamide, sulfonamide and amine compounds for metabolic disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130813

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140501

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140512

R150 Certificate of patent or registration of utility model

Ref document number: 5544296

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees